@FierceMedDev: Roche shells out up to $425M for superbug testing outfit. FierceDiagnostics news | Follow @FierceMedDev
@VarunSaxena2: ICYMI: Google joins forces with Dexcom for miniaturized glucose monitor. Article | Follow @VarunSaxena2
@EmilyWFierce: NICE plots takeover of England's Cancer Drugs Fund. FiercePharma article | Follow @EmilyWFierce
> Zyga Technologies received a 510(k) clearance from the FDA for its SImmetry System to treat lumbar spine conditions. More
> A study found that there is a need to increase the sharing of information between organ donors and their recipients. More
Biotech News
@FierceBiotech: FierceBiotech Radio on Amarin's First Amendment crusade, Martin Shkreli's Twitter, and Kim Kardashian's Instagram. Listen/Subscribe | Follow @FierceBiotech
@JohnCFierce: California cutbacks: Boston Sci to close two facilities, Abbott cuts 160+ employees. FierceMedicalDevices article | Follow @JohnCFierce
@DamianFierce: ICYMI: A wonderfully stern FDA official parses Kim Kardashian's Instagram. Letter | Follow @DamianFierce
> KemPharm spikes as its anti-abuse pain drug rolls toward the FDA. Story
> Lilly's CEO keeps faith in the pipeline as biotech gets 'too expensive.' Article
> CRO giant WuXi is going private in a $3.3B deal. News
> Avalanche hits the brakes on its gene therapy program after a Phase II misstep. Report
Pharma News
@FiercePharma: China FDA issues software guidelines on medical devices effective this month. FiercePharmaAsia story | Follow @FiercePharma
@EricPFierce: Sun U.S. sales gut-kicked by supply constraints as it works on FDA concerns at Halol plant. More from FiercePharmaManufacturing | Follow @EricPFierce
@CarlyHFierce: Biogen touts new Eloctate data as next-gen hemophilia rivals near the scene. FiercePharmaMarketing article | Follow @CarlyHFierce
> Novo says new U.S. plant may be best bet to offset the FX bite. More
> Shire raise its $30B Baxalta bid? It's going to need some details first. Article
> Takeda Actos settlement seems shaky as plaintiffs give it the sniff test. Story
> NICE plots takeover of England's Cancer Drugs Fund. Report